CNS Pharmaceuticals, Inc.(CNSP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CNSP CNS Pharmaceuticals, Inc.

Trading 03-20 11:29:56 EDT

2.25

+0.00

-0.22%

High2.29	Low2.25	Vol3.29K
Open2.29	D1 Closing2.25	Amplitude2.00%
Mkt Cap1.39M	Tradable Cap1.21M	Total Shares620.30K
T/O7.45K	T/O Rate0.61%	Tradable Shares539.50K
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CNSP","market":"US","secType":"STK","nameCN":"CNS Pharmaceuticals, Inc.","latestPrice":2.245,"timestamp":1774020383790,"preClose":2.25,"halted":0,"volume":3286,"delay":0,"changeRate":-0.002222222222222175,"floatShares":539500,"shares":620300,"eps":-22.749,"marketStatus":"Trading","change":-0.005,"latestTime":"03-20 11:29:56 EDT","open":2.29,"high":2.29,"low":2.245,"amount":7445.642905199999,"amplitude":0.02,"askPrice":2.3,"askSize":100,"bidPrice":2.16,"bidSize":160,"shortable":3,"etf":0,"ttmEps":-22.749,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1774036800000},"marketStatusCode":2,"adr":0,"listingDate":1573189200000,"exchange":"NASDAQ","adjPreClose":2.25,"postHourTrading":{"tag":"盘后","latestPrice":2.17,"preClose":2.17,"latestTime":"18:56 EDT","volume":22,"amount":50.57,"timestamp":1773960993743,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.1827},"requestUrl":"/m/hq/s/CNSP","defaultTab":"news","newsList":[{"id":"2618329940","title":"CNS Pharmaceuticals launches new corporate growth strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2618329940","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618329940?lang=en_us&edition=fundamental","pubTime":"2026-03-11 20:52","pubTimestamp":1773233524,"startTime":"0","endTime":"0","summary":"CNS Pharmaceuticals (CNSP) has launched a new corporate growth strategy designed to build a high-value pipeline in neurology and oncology. The stra...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cns-pharmaceuticals-launches-new-corporate-growth-strategy-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cns-pharmaceuticals-launches-new-corporate-growth-strategy-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","CNS","BK4135","CNSP"],"gpt_icon":0},{"id":"2618947895","title":"CNS Pharmaceuticals to Pursue Acquisition and In-Licensing of Neurology and Oncology Assets, While Exploring Out-Licensing of Berubicin and TPI 287 to Build a New Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2618947895","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618947895?lang=en_us&edition=fundamental","pubTime":"2026-03-11 20:35","pubTimestamp":1773232515,"startTime":"0","endTime":"0","summary":"CNS Pharmaceuticals to Pursue Acquisition and In-Licensing of Neurology and Oncology Assets, While Exploring Out-Licensing of Berubicin and TPI 287 to Build a New Pipeline. CNS Pharmaceuticals Inc. announced a corporate growth strategy to build a higher-value pipeline in neurology and oncology. The company plans to conduct a global search to identify, acquire or in-license preclinical and clinical-stage assets, prioritizing programs with differentiated mechanisms, clear development and regulatory pathways, and defined value inflection points targeting unmet medical needs. CNS Pharmaceuticals also plans to prepare partnering packages to explore out-licensing its legacy assets, berubicin and TPI 287, as it shifts resources toward an acquisition-driven pipeline.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nNDL36HBpM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNSP","BK4007"],"gpt_icon":0},{"id":"2617693564","title":"CNS Pharmaceuticals Files Initial Beneficial Ownership Statement for CFO Steve O’Loughlin","url":"https://stock-news.laohu8.com/highlight/detail?id=2617693564","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617693564?lang=en_us&edition=fundamental","pubTime":"2026-03-05 06:00","pubTimestamp":1772661658,"startTime":"0","endTime":"0","summary":"CNS Pharmaceuticals Inc. filed an initial statement of beneficial ownership naming Steve O’Loughlin, Chief Financial Officer, as the reporting person. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CNS Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 04, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nNDL2dWp7m:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNSP","BK4007"],"gpt_icon":0},{"id":"2616337412","title":"CNS Pharmaceuticals names Lynne Kelley chief medical officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2616337412","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616337412?lang=en_us&edition=fundamental","pubTime":"2026-03-02 21:25","pubTimestamp":1772457933,"startTime":"0","endTime":"0","summary":"CNS Pharmaceuticals Inc. appointed Lynne Kelley, MD, FACS, as Chief Medical Officer, completing its executive leadership team. Kelley brings more than 20 years of experience in clinical development, translational medicine and regulatory strategy across oncology, rare diseases, CNS and medical devices, and previously served as chief medical officer at several biotechnology and medical device companies.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nNDL6qHNLw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNSP","BK4007"],"gpt_icon":0},{"id":"2612452457","title":"CNS Pharmaceuticals Inc - Appoints Steve O'loughlin as CFO, Effective March 2 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2612452457","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612452457?lang=en_us&edition=fundamental","pubTime":"2026-02-17 21:37","pubTimestamp":1771335451,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nFWN3ZD0SI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CNSP"],"gpt_icon":0},{"id":"2612437457","title":"CNS Pharmaceuticals Sets New Executive Compensation Agreements","url":"https://stock-news.laohu8.com/highlight/detail?id=2612437457","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612437457?lang=en_us&edition=fundamental","pubTime":"2026-02-17 21:36","pubTimestamp":1771335390,"startTime":"0","endTime":"0","summary":"CNS Pharmaceuticals Inc. has appointed Steve O'Loughlin as Chief Financial Officer effective March 2, 2026, with an initial annual base salary of $450,000 and eligibility for an annual bonus targeted at 40% of base salary, as well as annual equity grants. Christopher Downs, the current CFO, will become Senior Vice President - Finance with an annual base salary of $350,000 and a target annual bonus of 30% of base salary, along with eligibility for equity grants. Both executives are entitled to six months of base salary as severance if terminated without cause or for good reason.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CNS Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electroni","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nNDL3Nz4VH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNSP","BK4007"],"gpt_icon":0},{"id":"2612573794","title":"CNS Pharmaceuticals Names New CEO and Executive Team","url":"https://stock-news.laohu8.com/highlight/detail?id=2612573794","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612573794?lang=en_us&edition=fundamental","pubTime":"2026-02-17 21:25","pubTimestamp":1771334715,"startTime":"0","endTime":"0","summary":"CNS Pharmaceuticals Inc. has announced new additions to its executive team, effective March 2, 2026. Rami Levin is the recently appointed President and CEO. Steven O'Loughlin will serve as Chief Financial Officer, Eric Faulkner as Chief Technology Officer, and Dylan Wenke as Chief Business Officer. These appointments are part of the company’s strategic transformation aimed at advancing its development of treatments for brain and central nervous system cancers.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nNDL606J3c:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CNSP"],"gpt_icon":0},{"id":"2606738084","title":"CNS Pharmaceuticals Inc. Outlines Strategy to Sharpen Focus, Optimize Pipeline, and Align Capital Allocation for Long-Term Value Creation","url":"https://stock-news.laohu8.com/highlight/detail?id=2606738084","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606738084?lang=en_us&edition=fundamental","pubTime":"2026-01-27 22:51","pubTimestamp":1769525463,"startTime":"0","endTime":"0","summary":"CNS Pharmaceuticals Inc. Outlines Strategy to Sharpen Focus, Optimize Pipeline, and Align Capital Allocation for Long-Term Value Creation. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CNS Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire  on January 27, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260127:nNDL2zSFrD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CNSP"],"gpt_icon":0},{"id":"2606804447","title":"CNS Pharmaceuticals says priority ‘is to transform’ how company operates","url":"https://stock-news.laohu8.com/highlight/detail?id=2606804447","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606804447?lang=en_us&edition=fundamental","pubTime":"2026-01-27 22:15","pubTimestamp":1769523345,"startTime":"0","endTime":"0","summary":"CNS Pharmaceuticals (CNSP) issued a Letter to Shareholders from its newly appointed President and CEO Rami Levin, which read in part, “I am honored...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cns-pharmaceuticals-says-priority-is-to-transform-how-company-operates-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cns-pharmaceuticals-says-priority-is-to-transform-how-company-operates-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CNS","CNSP","BK4007","BK4135"],"gpt_icon":0},{"id":"2603986180","title":"CNS Pharmaceuticals Inc trading halted, volatility trading pause","url":"https://stock-news.laohu8.com/highlight/detail?id=2603986180","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603986180?lang=en_us&edition=fundamental","pubTime":"2026-01-15 22:35","pubTimestamp":1768487744,"startTime":"0","endTime":"0","summary":"09:32 EST CNS Pharmaceuticals (CNSP) Inc trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-time, ma...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cns-pharmaceuticals-inc-trading-halted-volatility-trading-pause-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cns-pharmaceuticals-inc-trading-halted-volatility-trading-pause-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4135","BK4007","CNSP","CNS"],"gpt_icon":0},{"id":"2603986332","title":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 09:32 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2603986332","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603986332?lang=en_us&edition=fundamental","pubTime":"2026-01-15 22:32","pubTimestamp":1768487552,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 09:32 AM","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260115:nAQN2LHT8X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CNSP"],"gpt_icon":0},{"id":"2600937170","title":"CNS Pharmaceuticals Inc. Files Initial Statement of Beneficial Ownership for CEO and President Rami Levin","url":"https://stock-news.laohu8.com/highlight/detail?id=2600937170","media":"Reuters","labels":["executive","shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600937170?lang=en_us&edition=fundamental","pubTime":"2026-01-03 06:00","pubTimestamp":1767391232,"startTime":"0","endTime":"0","summary":"CNS Pharmaceuticals Inc. has filed an initial statement of beneficial ownership with the U.S. Securities and Exchange Commission. The filing identifies Rami Levin as the beneficial owner, who serves as the company’s CEO, President, and Director. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CNS Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 02, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260102:nNDL4rznmN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"CNS Pharmaceuticals Inc. Files Initial Statement of Beneficial Ownership for CEO and President Rami Levin","news_tag":"executive,shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CNSP"],"gpt_icon":0},{"id":"2592918027","title":"CNS Pharmaceuticals Inc - Appoints Rami Levin as CEO Effective Jan 1, 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2592918027","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592918027?lang=en_us&edition=fundamental","pubTime":"2025-12-17 21:46","pubTimestamp":1765979189,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nFWN3XN133:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CNSP"],"gpt_icon":0},{"id":"2592918021","title":"CNS Pharmaceuticals Inc - John Climaco Resigns as CEO and Board Member Effective Dec 16, 2025 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2592918021","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592918021?lang=en_us&edition=fundamental","pubTime":"2025-12-17 21:46","pubTimestamp":1765979189,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nFWN3XN133:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CNSP"],"gpt_icon":0},{"id":"2592992388","title":"CNS Pharmaceuticals Appoints Rami Levin as CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2592992388","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592992388?lang=en_us&edition=fundamental","pubTime":"2025-12-17 20:02","pubTimestamp":1765972921,"startTime":"0","endTime":"0","summary":"CNS Pharmaceuticals Inc. has announced the appointment of Rami Levin as its new President and Chief Executive Officer, effective January 1, 2026. John Climaco has stepped down from his role as CEO. Rami Levin brings experience from previous leadership positions at Saniona, ImStem Biotechnology, Sobi, Merck Serono, and Schering AG.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CNS Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire  on December 17, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nNDL1r51VJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNSP","BK4007"],"gpt_icon":0},{"id":"2585743129","title":"CNS Pharmaceuticals Held Annual Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2585743129","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585743129?lang=en_us&edition=fundamental","pubTime":"2025-11-22 06:19","pubTimestamp":1763763597,"startTime":"0","endTime":"0","summary":"CNS Pharmaceuticals Inc. held its Annual Meeting of Stockholders on November 17, 2025. Shareholders approved amendments to the company's 2020 Equity Plan, increasing the number of shares authorized for issuance under the plan. The meeting also saw the election of John Climaco, Jerzy  Gumulka, Jeffry R. Keyes, Faith Charles, Bettina Cockroft, and Amy Mahery to the board of directors. In addition, shareholders approved amendments to the company's Articles of Incorporation to increase the total number of authorized shares of common stock from 25,000,000 to 300,000,000 and the total number of authorized shares of preferred stock from 416,667 to 5,000,000.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CNS Pharmaceuticals Inc. published the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251121:nNDL9lKggK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CNSP"],"gpt_icon":0},{"id":"2584264036","title":"CNS Pharmaceuticals reports Q3 net loss of $3.3 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2584264036","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584264036?lang=en_us&edition=fundamental","pubTime":"2025-11-17 21:35","pubTimestamp":1763386522,"startTime":"0","endTime":"0","summary":"CNS Pharmaceuticals Inc. reported a net loss of approximately $3.3 million for the three months ended September 30, 2025, compared to a net loss of $5.6 million for the same period in 2024. Research and development expenses were $2.2 million, down from $4.2 million in the prior year period. General and administrative expenses were $1.1 million, compared to $1.4 million in the third quarter of 2024. The company stated its cash is expected to fund operations into the second half of 2026. During the period, CNS Pharmaceuticals focused on advancing its lead program, TPI 287, for glioblastoma multiforme, progressing toward a Phase 2 study and planning to engage with the FDA on study design in early 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or leg","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nNDLZz49K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNSP","BK4007"],"gpt_icon":0},{"id":"2582874161","title":"CNS Pharmaceuticals Unveils New Glioblastoma and Pediatric DMG Clinical Trial Results at SNO 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2582874161","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582874161?lang=en_us&edition=fundamental","pubTime":"2025-11-10 21:45","pubTimestamp":1762782325,"startTime":"0","endTime":"0","summary":"CNS Pharmaceuticals Inc. has announced the acceptance of three abstracts for poster presentation at the 2025 Society of Neuro-Oncology  Annual Meeting, scheduled for November 19-23, 2025, in Honolulu, Hawaii. The presentations will cover preliminary data on the activity of Berubicin against pediatric diffuse midline glioma  cells, the evaluation of TPI 287 in combination with Bevacizumab in glioblastoma  and other central nervous system diseases, and the primary results of a randomized clinical trial comparing Berubicin versus Lomustine in patients with glioblastoma after failure of primary therapy. The results of these studies will be presented at the SNO meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CNS Pharmaceuticals Inc.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDLXD0Cq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CNSP"],"gpt_icon":0},{"id":"2574189107","title":"CNS Pharmaceuticals Inc announces date for annual stockholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2574189107","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574189107?lang=en_us&edition=fundamental","pubTime":"2025-10-11 04:31","pubTimestamp":1760128301,"startTime":"0","endTime":"0","summary":"CNS Pharmaceuticals Inc. has announced that its Annual Meeting of Stockholders will be held virtually on November 17, 2025. During the meeting, stockholders will vote on the election of six nominees to the Board of Directors, each to serve until the 2026 annual meeting of stockholders or until their successors are qualified and elected.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CNS Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 10, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251010:nNDL37Z9cC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNSP","BK4007"],"gpt_icon":0},{"id":"2566131977","title":"CNS Pharmaceuticals Raised to Buy From Hold by Maxim Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2566131977","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566131977?lang=en_us&edition=fundamental","pubTime":"2025-09-12 22:18","pubTimestamp":1757686680,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CNSP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 12, 2025 10:18 ET (14:18 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNSP","CNS"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cnspharma.com","stockEarnings":[{"period":"1week","weight":-0.2359},{"period":"1month","weight":-0.3344},{"period":"3month","weight":-0.6667},{"period":"6month","weight":-0.7281},{"period":"1year","weight":-0.9525},{"period":"ytd","weight":-0.5867}],"compareEarnings":[{"period":"1week","weight":-0.0094},{"period":"1month","weight":-0.0338},{"period":"3month","weight":-0.0305},{"period":"6month","weight":-0.0059},{"period":"1year","weight":0.1634},{"period":"ytd","weight":-0.0324}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.","yearOnYearQuotes":[{"month":1,"riseRate":0.285714,"avgChangeRate":-0.159728},{"month":2,"riseRate":0.285714,"avgChangeRate":-0.133209},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.221749},{"month":4,"riseRate":0.333333,"avgChangeRate":0.014485},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.010143},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.175576},{"month":7,"riseRate":0.166667,"avgChangeRate":-0.241438},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.118916},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.104014},{"month":10,"riseRate":0.166667,"avgChangeRate":0.050333},{"month":11,"riseRate":0.5,"avgChangeRate":-0.052563},{"month":12,"riseRate":0.142857,"avgChangeRate":-0.198237}],"exchange":"NASDAQ","name":"CNS Pharmaceuticals, Inc.","nameEN":"CNS Pharmaceuticals, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CNS Pharmaceuticals, Inc.(CNSP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest CNS Pharmaceuticals, Inc.(CNSP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"CNS Pharmaceuticals, Inc.,CNSP,CNS Pharmaceuticals, Inc.股票,CNS Pharmaceuticals, Inc.股票老虎,CNS Pharmaceuticals, Inc.股票老虎国际,CNS Pharmaceuticals, Inc.行情,CNS Pharmaceuticals, Inc.股票行情,CNS Pharmaceuticals, Inc.股价,CNS Pharmaceuticals, Inc.股市,CNS Pharmaceuticals, Inc.股票价格,CNS Pharmaceuticals, Inc.股票交易,CNS Pharmaceuticals, Inc.股票购买,CNS Pharmaceuticals, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CNS Pharmaceuticals, Inc.(CNSP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest CNS Pharmaceuticals, Inc.(CNSP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}